• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Anebulo Pharmaceuticals Inc (NQ: ANEB )

    2.200 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 310
    Open 2.200
    Bid (Size) 2.210 (3)
    Ask (Size) 2.400 (4)
    Prev. Close 2.200
    Today's Range 2.200 - 2.200
    52wk Range 1.620 - 4.050
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Lifecore Biomedical Announces Cooperation Agreement with 22NW
    Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
    From Lifecore Biomedical, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -10.96%
    -10.96%
    1 Month
    -17.91%
    -17.91%
    3 Month
    -20.00%
    -20.00%
    6 Month
    -11.65%
    -11.65%
    1 Year
    +1.85%
    +1.85%

    More News

    Read More
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
    Via Benzinga
    Anebulo Pharmaceuticals: Q3 Earnings Insights
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024
    Via InvestorPlace
    Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
    Via Benzinga
    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Anebulo Pharmaceuticals Announces New CEO
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
    Via Benzinga
    Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
    From Anebulo Pharmaceuticals, Inc.
    Via Business Wire
    Antidote For THC? Anebulo Releases Positive Clinical Data Showing Potential Of Its Drug For Treatment Of Acute Cannabinoid Intoxication
    Via Benzinga
    Latest Executive Changes In Marijuana Industry, New Appointments & Resignations
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.